Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Telix Pharmaceuticals (TLX) Other Non-Current Assets (2023 - 2025)

Telix Pharmaceuticals (TLX) posted Other Non-Current Assets of $28.8 million for Q4 2025, up 79.31% on a QoQ basis from $16.1 million in Q4 2024, and up 79.31% year-over-year from $16.1 million in Q4 2024.

Telix Pharmaceuticals (TLX) has 3 years of Other Non-Current Assets data on file, last reported at $28.8 million in Q4 2025.

  • In Q4 2025, Other Non-Current Assets rose 79.31% year-over-year to $28.8 million; the TTM figure through Dec 2025 stood at $28.8 million (up 79.31% YoY), while the FY2025 annual figure was $28.8 million, up 91.0% from the prior year.
  • Other Non-Current Assets grew to $28.8 million in Q4 2025, from $16.1 million in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $28.8 million in Q4 2025 and bottomed at $381480.4 in Q4 2023.
  • A 3-year average of $15.1 million and a median of $16.1 million in 2024 frame the typical range for Other Non-Current Assets.
  • Annual changes were most pronounced in 2024 — Other Non-Current Assets surged 4113.99% — and 2025, when it jumped 79.31%.
  • Year by year, Other Non-Current Assets stood at $381480.4 in 2023, then surged by 4113.99% to $16.1 million in 2024, then jumped by 79.31% to $28.8 million in 2025.
  • The last three Other Non-Current Assets figures came in at $28.8 million (Q4 2025), $16.1 million (Q4 2024), and $381480.4 (Q4 2023), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Other Non-Current Assets (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn 12.40 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - 60,000.00
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 1.26 Bn
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 2.13 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 63.55 Mn
10 Telix Pharmaceuticals 4.52 Bn 4.38 Bn - 28.83 Mn

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 28.83 Mn
Dec 31, 2024 16.08 Mn
Dec 31, 2023 381,480.42